SUMMIT: No Impact From Baseline eGFR on HF Outcomes With Tirzepatide
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
57 
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR?Preserved analysis
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide. Patients who developed LRTI had a 2.7-fold
Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and meta‐analysis
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidney disease (ESKD) undergoing dialysis is limited.
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Circulation: Heart Failure
NOVEMBER 25, 2024
Spironolactone reduced HF events in some patients with HF with preserved ejection fraction, but the results were not generalizable to all patients with HF with preserved ejection fraction. The use of MRAs has been limited due to excessive concern about hyperkalemia.
Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry
Open Heart
APRIL 24, 2024
HF with preserved ejection fraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3% Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). and 29.2%, p<0.001).
Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure
DAIC
MARCH 26, 2025
live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 Bozkurt A, et al.
Let's personalize your content